Dried Urine GCMS Estrogen Hormone Metabolites

Oestrone is the predominant circulating oestrogen after menopause, synthesised peripherally from androstenedione in adipose tissue and adrenal cortex. Before menopause the ovary produces it directly and via aromatisation; following ovarian senescence peripheral conversion becomes the principal source. Urinary measurement reflects integrated tissue production rather than the pulsatile serum pattern.

E1 levels inform overall oestrogenic status in postmenopausal and perimenopausal women. Elevated postmenopausal oestrone — often driven by adiposity — is associated with increased endometrial and breast cancer risk, while low levels may contribute to bone loss and vasomotor symptoms.

Oestradiol is the most potent oestrogen during reproductive years, secreted by ovarian granulosa cells under FSH and LH control. It drives endometrial proliferation, secondary sexual characteristics, and bone mineralisation. Urinary E2 captures both free and conjugated fractions excreted over the collection window.

Urinary E2 is used to assess ovarian function, monitor hormone replacement, and evaluate oestrogenic load. Low E2 is seen in hypogonadism, ovarian insufficiency, and functional hypothalamic amenorrhoea; high E2 may indicate oestrogen dominance, ovarian tumours, or exogenous sources.

Oestriol is a weaker oestrogen produced in small amounts outside pregnancy via 16α-hydroxylation of oestrone and oestradiol. During pregnancy the foetal-placental unit generates large quantities. Urinary E3 reflects hepatic and peripheral metabolism of parent oestrogens.

In non-pregnant women E3 is a minor metabolite; some practitioners view higher E3 relative to E1 and E2 as a favourable metabolic pattern. Elevated E3 in pregnancy is monitored in specific foetal assessments, though that is beyond the scope of this adult hormone panel.

2-Hydroxyestrone is formed by cytochrome P450 1A1 and 1A2 hydroxylation of oestrone at the C2 position. It has weak oestrogenic activity and is catabolised rapidly via catechol-O-methyltransferase to methoxyoestradiols, which are excreted. This pathway is considered the predominant 'protective' route of oestrogen metabolism.

Higher 2-OH-E1 is associated in epidemiological and mechanistic studies with lower breast and endometrial cancer risk. Practitioners use the 2-OH to 16α-OH ratio as a marker of metabolic balance; a higher ratio is interpreted as favourable.

4-Hydroxyestrone is generated by cytochrome P450 1B1 hydroxylation at the C4 position. Unlike 2-OH metabolites, 4-OH catechols can form reactive quinones that bind DNA and generate oxidative adducts, a mechanism implicated in oestrogen-induced carcinogenesis in experimental models.

Elevated 4-OH-E1 is considered a biomarker of increased genotoxic risk. Functional and integrative practitioners monitor it as part of cancer-risk stratification, especially in women with family history or dense breast tissue, though prospective validation in clinical cohorts remains limited.

16α-Hydroxyestrone is produced by cytochrome P450 3A4 and other enzymes via hydroxylation at the C16α position. It retains significant oestrogenic potency, binds covalently to the oestrogen receptor, and stimulates cellular proliferation more persistently than parent oestrogens.

Higher 16α-OH-E1 has been associated in some case-control and mechanistic studies with increased breast cancer risk, though findings are inconsistent. The 2:16α ratio is used in functional medicine as a metabolic risk index; lower ratios prompt dietary and supplemental interventions.

The 2:16α ratio quantifies the balance between the putatively protective 2-hydroxylation pathway and the more proliferative 16α pathway. It reflects the composite activity of competing cytochrome P450 isoforms, influenced by genetics, diet (cruciferous vegetables, fibre), obesity, and xenobiotic exposure.

A higher 2:16α ratio has been associated with lower breast cancer risk in early case-control studies, though larger prospective cohorts have yielded mixed results. Functional practitioners use it to guide dietary and supplement interventions (indole-3-carbinol, DIM, flaxseed), but its predictive value for individual cancer risk remains contested.

2-Methoxyestrone is formed when catechol-O-methyltransferase methylates 2-hydroxyestrone, inactivating it and facilitating renal excretion. COMT activity is influenced by the common Val158Met polymorphism, dietary methyl donors, and magnesium status.

Measurement of methylated catechols provides insight into phase II conjugation efficiency. Low 2-MeOE1 relative to 2-OH-E1 may indicate impaired COMT activity or methyl-donor insufficiency, prompting evaluation of B12, folate, and magnesium status.

4-Methoxyestrone is the COMT-methylated product of 4-hydroxyestrone. Methylation of 4-OH catechols is critical to prevent their oxidation to DNA-damaging quinones, so the balance between 4-OH-E1 and 4-MeOE1 reflects detoxification efficiency.

A low 4-MeOE1:4-OH-E1 ratio suggests sluggish COMT activity and higher genotoxic potential. This pattern is used in functional medicine to guide methylation support and antioxidant strategies, though clinical validation is limited.